Tevogen Expands PredicTcell™ Beta Data 100x, Advancing AI-Powered T Cell Therapy Precision and Efficacy

Tevogen Bio Holdings Inc. (Nasdaq: TVGN) announced a major advancement in its AI-driven immunotherapy platform, revealing a 100x expansion of its PredicTcell™ beta data set. The milestone marks a critical step forward in enhancing the precision and efficacy of T cell–based therapies for treating infectious diseases and cancer. The PredicTcell™ platform, developed in collaboration with Microsoft and Databricks, leverages machine learning and transformer-based models to predict immunologically active peptide-T cell receptor interactions. The alpha version of the model was trained on over 124,000 records using transformer architecture and 91,000 records with traditional machine learning, achieving a recall rate of 92–97% and precision between 38–43%. These results validated the platform’s potential as a tool for identifying effective T cell targets. Building on this foundation, the beta version of PredicTcell has been significantly enhanced through expanded data pipelines and refined model training. The goal is to dramatically improve precision in identifying virology targets, with the ultimate aim of enabling T cell therapies that bind to their intended targets with near certainty. Mittul Mehta, CIO and Head of Tevogen.AI, emphasized the transformative potential of the platform: “The promise of PredicTcell goes far beyond data. If our tools continue to deliver as expected, Tevogen could create T-cell therapies where binding to the target virus or disease isn’t just likely—it’s nearly guaranteed. This level of predictability could lead to faster cures, lower costs, and more lives saved.” Ryan Saadi, M.D., M.P.H., CEO of Tevogen Bio, added, “By combining cutting-edge AI with deep biological insight from our ExacTcell™ platform and clinical data from our Phase 1 trials, we’re raising the bar for T cell therapy development. This initiative is designed to increase efficacy, reduce costs, and open new frontiers in precision medicine.” The company highlighted that the expanded data capacity and advanced modeling are made possible through cloud infrastructure powered by Microsoft and data engineering tools from Databricks, enabling scalable and efficient AI training. Tevogen cautioned that the announcement includes forward-looking statements regarding future research, development, commercialization, and growth. These statements are subject to risks and uncertainties, including the need for additional capital, regulatory challenges, competition, technological changes, and the ability to execute on its strategy. Actual results may differ materially due to these and other factors. The company reiterated that forward-looking statements reflect management’s views as of the date of release and are not obligations to update them, except as required by law. For media inquiries, contact Tevogen Bio Communications at 1-877-TEVOGEN, Ext. 701, or via email at Communications@Tevogen.com.